These pocket guidelines provide evidence-based guidance on how to reduce the incidence of first and recurrent clinical events due to coronary heart disease (CHD), cerebrovascular disease (CeVD) and peripheral vascular disease in two categories of people
This document provides Technical content on ZIKV, its manifestations, complications, modes of transmission, and prevention measures to be used in answering frequently asked questions and conveying messages in information and communication materials, community talks, press conferences, etc.
A Guidance and Resource Package for Country Offices for Coordination, Planning, Key Messages and Actions
This document offers suggested risk communication actions in relation to Zika virus infection and other health issues linked to this disease. It is directed toward ministers of health and other health sector actors who, with their national (multidisciplinary) teams for communication and social mobil...ization, will be able to adapt the provided information to the needs of their countries and audiences.
more
Djibuti et al. BMC Public Health (2015) 15:427 DOI 10.1186/s12889-015-1760-z
J Epidemiol Community Health 2011;65:1166e1170. doi:10.1136/jech.2009.097469
Treating children infected with intestinal worms is one of the simplest and most cost–effective ways to improve their health.
The recommendations are intended for a wide audience, including policy-makers and their expert advisers as well as technical and programme staff at government institution...s and organizations involved in the design, implementation and expansion of programmes to control soil-transmitted helminth infections.
more
Participant Manual
October 2009
This guideline covers making people aware of how to correctly use antimicrobial medicines (including antibiotics) and the dangers associated with their overuse and misuse. It also includesmeasures to prevent and control infection that can stop people needing antimicrobials or spreadinginfection to o...thers. It aims to change people's behaviour to reduce antimicrobial resistance and thespread of resistant microbes.
more
To provide recommendations on the initial care of persons with acute respiratory illness (ARI) in the context of coronavirus disease (COVID-19) in healthcare facilities based on a decision-making process flowchart. These recommendations are preliminary and subject to review as new evidence becomes a...vailable. The recommendations provided in this document apply for adults olden than 18 years old.
more
10 July 2020
Guidance for authorities and event organizers planning mass gatherings during the current COVID-19 pandemic
The content of this Risk Assessment tool has been updated to reflect new WHO guidance and new evidence on both COVID-19 and mass gatherings, as well as feedback from end-users.
...
Additional improvements have been made to the way the information is organized and presented: the Decision Tree is now built into the tool and a new tab dedicated to Risk Communication has been added. The expanded tool now includes six tabs: 1. Instructions; 2. Decision Tree; 3. Risk Evaluation; 4. Risk Mitigation; 5. Decision Matrix; 6. Risk Communication.
more
Abridged version. In this abridged version of the Evidence-based Clinical Practice Guidelines for the Follow-Up of at-risk neonates, we provide recommendations for the care of newborns up to 2 years of age, corresponding to the first phase of their follow-up. The recommendations are intended for all... health sector staff responsible for the primary care of these neonates: general practitioners, family practitioners, pediatricians, neonatologists, pediatric ophthalmologists, pediatric otolaryngologists, nursing professionals, specialists in other fields, and multidisciplinary staff involved in the care process. The purpose of these guidelines is to facilitate policy implementation processes carried out by decision-makers and members of government bodies, and will also be useful for parents, mothers, and caregivers. The main topics covered by this document include the hospital discharge criteria, including screening tests; information and support for parents, mothers, and caregivers; screening at the follow-up visit, and the frequency of follow-ups until the infant is 2 years of age. These guidelines do not address matters related to nursing or comorbidities.
more
A rapid review of evidence on the managing the risk of disease emergence in the wildlife trade - World Animal Health Organization (OIE)
The guidance notes describe key actions that policy-makers at national and subnational levels can take in relation to: diagnostic testing for COVID-19, clinical management of COVID-19, meeting targets for vaccination against COVID-19, maintaining infection control measures for COVID-19 in health-car...e settings, building confidence through risk communication and community involvement, and ensuring that all health-care workers are aware of the risks of COVID-19.
This guidance note focuses on the following areas: COVID-19 diagnostic testing, clinical management of COVID-19, achieving COVID-19 vaccination targets, maintaining COVID-19 infection control measures in health-care settings, building confidence through risk communication and community engagement, and managing COVID-19 infodemia. This guidance note focuses on risk communication and community engagement in the context of COVID-19.
more
The coronavirus disease (COVID-19) pandemic exacerbated pre-existing inequalities in the treatment and care of noncommunicable diseases (NCDs). This report examines the effect of the COVID-19 pandemic on access to NCD medicines, and the policies and strategies implemented by countries and health sys...tems to anticipate and mitigate stresses across NCD medicine supply chains. The full range of upstream and downstream impacts are investigated, including: manufacturing; procurement, importation and last mile delivery; patient-level effects through affordability and availability; and the effects on NCD medicine availability by category of disease. The report culminates in recommended actions and interventions for key stakeholders in the NCD pharmaceutical supply chain, including governments, regulatory authorities, manufacturers and the private sector; as well as directions for future research for improving access and supply chain access resilience.
more